Adamis Pharmaceuticals Corporation Net Income 2011-2026 | ADMP

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.^[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income Adamis Pharmaceuticals Corporation

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-26.5 M	-45.8 M	-49.4 M	-29.3 M	-39 M	-25.5 M	-19.4 M	-13.6 M	-8.16 M	-7.19 M	-4.92 M	-6.98 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-4.92 M	-49.4 M	-23 M

Quarterly Net Income Adamis Pharmaceuticals Corporation

2023-Q3	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-1.39 M	-8.94 M	-	-4.4 M	-8.4 M	-10.4 M	-	-12.4 M	-9.31 M	-15.4 M	-	-11.4 M	-12.9 M	-7.25 M	-	-7 M	-7.74 M	-8.89 M	-	-8.88 M	-9.7 M	-7.62 M	-	-6.77 M	-4.97 M	-5.77 M	-	-6.64 M	-5.71 M	-6.41 M	-	-3.15 M	-3.64 M	-3.14 M	-	-2.12 M	-2.88 M	-1.55 M	-5.53 M	-32 K	-1.07 M	-	-1.97 M	-5.56 M	-3.58 M	-	-991 K	-3.71 M	-2.72 M	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-32 K	-15.4 M	-6.05 M

References

Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Drug manufacturers industry

Issuer	Net Income	Price	% 24h	Market Cap	Country
AcelRx Pharmaceuticals ACRX	-14.3 M	-	7.5 %	$ 6.35 M	USA
Alimera Sciences ALIM	-20.1 M	-	-	$ 142 M	USA
Aerie Pharmaceuticals AERI	-74.8 M	-	-	$ 754 M	USA
Agile Therapeutics AGRX	-14.5 M	-	10.11 %	$ 58.2 M	USA
China Pharma Holdings CPHI	-4.74 M	$ 0.57	-9.62 %	$ 9.95 M	China
Eagle Pharmaceuticals EGRX	35.6 M	-	-39.89 %	$ 27.7 M	USA
Aurora Cannabis ACB	-695 M	$ 3.32	0.3 %	$ 86.3 M	Canada
Catalent CTLT	-1.04 B	-	-	$ 11.5 B	USA
Athenex ATNX	-103 M	-	-23.39 %	$ 1.76 M	USA
Avadel Pharmaceuticals plc AVDL	-48.8 M	-	-	$ 2.06 B	France
Cronos Group CRON	-73.1 M	$ 2.58	2.38 %	$ 1.34 B	Canada
DURECT Corporation DRRX	-27.6 M	-	-	$ 50.1 M	USA
Emergent BioSolutions EBS	-760 M	$ 8.01	-0.5 %	$ 410 M	USA
Endo International plc ENDP	-2.45 B	-	-	$ 28.9 M	Irlanda
Evoke Pharma EVOK	-7.79 M	-	-	$ 36.6 M	USA
Calliditas Therapeutics AB (publ) CALT	-510 M	-	-0.1 %	$ 2.03 B	Schweden
HEXO Corp. HEXO	-115 M	-	2.45 %	$ 38.1 M	Canada
Cumberland Pharmaceuticals CPIX	-1.9 M	$ 3.13	2.62 %	$ 44 M	USA
Neoleukin Therapeutics NLTX	-90.4 M	-	-	$ 193 M	Canada
Bausch Health Companies BHC	-592 M	$ 4.99	-2.25 %	$ 1.82 B	Canada
Pacira BioSciences PCRX	-99.6 M	$ 23.2	2.43 %	$ 1.07 B	USA
Harrow Health HROW	-5.14 M	$ 35.2	3.53 %	$ 1.29 B	USA
PetIQ PETQ	2.13 M	-	1.64 %	$ 400 M	USA
OptiNose OPTN	-35.5 M	-	-	$ 1.08 B	USA
PLx Pharma PLXP	-46.1 M	-	-27.8 %	$ 2.56 M	USA
Perrigo Company plc PRGO	-1.43 B	$ 9.64	0.73 %	$ 1.34 B	USA
ProPhase Labs PRPH	18.5 M	-	-	$ 5.07 M	USA
Evolus EOLS	-51.6 M	$ 4.43	-5.34 %	$ 286 M	USA
Radius Health RDUS	-70.2 M	-	-	$ 1.42 B	USA
Sundial Growers SNDL	-230 M	$ 1.37	0.74 %	$ 3.37 M	Canada
Rockwell Medical RMTI	-8.44 M	$ 1.03	0.98 %	$ 24 M	USA
Relmada Therapeutics RLMD	-57.4 M	$ 6.1	4.1 %	$ 241 M	USA
OrganiGram Holdings OGI	-131 M	$ 1.34	-1.47 %	$ 402 M	Canada
SCYNEXIS SCYX	-8.61 M	$ 0.9	2.8 %	$ 44.9 M	USA
Jupiter Wellness JUPW	-49.4 M	-	-	$ 33.6 M	USA
Solid Biosciences SLDB	-174 M	$ 6.68	-6.44 %	$ 585 M	USA
Lannett Company LCI	-232 M	-	1.15 %	$ 7.11 M	USA
Sonoma Pharmaceuticals SNOA	-3.46 M	$ 2.34	-8.24 %	$ 2.9 M	USA
Organogenesis Holdings ORGO	861 K	$ 2.41	-2.43 %	$ 317 M	USA
Canopy Growth Corporation CGC	-598 M	$ 0.96	-0.87 %	$ 103 M	Canada
Tilray TLRY	-1.45 B	$ 6.66	3.26 %	$ 4.12 B	Canada
Assertio Holdings ASRT	-30.4 M	$ 16.51	17.93 %	$ 106 M	USA
TherapeuticsMD TXMD	-10.3 M	$ 2.29	-0.87 %	$ 23.9 M	USA
Recro Pharma REPH	-13.3 M	-	-4.76 %	$ 65.3 M	USA
Veru VERU	-37.8 M	$ 2.29	-0.43 %	$ 309 M	USA
Viatris VTRS	54.7 M	$ 13.36	0.53 %	$ 16 B	USA
cbdMD YCBD	-153 K	$ 0.77	1.06 %	$ 3.32 M	USA
Tricida TCDA	-177 M	-	-	$ 3.25 M	USA
Zynerba Pharmaceuticals ZYNE	-35 M	-	-	$ 55.5 M	USA